Аннотация:93respectively).However, among patients who received sunitinib, grade 3 or 4 treatment-related adverse events were higher among those in the older age group (55% vs. 70%).Our results support an age-independent benefit-risk profile of nivolumab plus ipilimumab, including in elderly patients.Clinical data are lacking to assess any distinctive changes in the cellular immune response to checkpoint inhibitors as a function of age.
